In conclusion, despite the proliferative effect of GH, our data suggest that short-term administration of GH concomitant with radiotherapy exerts a dual action, preventing radiation injury to the intestine while not protecting the tumor, preserving the therapeutic potential of the treatment. The gene discussed is GH1; the disease is neoplasm.